REVIEW

Antioestrogen-mediated cell cycle arrest and apoptosis induction in breast cancer and multiple myeloma cells

Jack-Michel Renoir^{1,2,3}, Céline Bouclier^{1,2,3}, Amélie Seguin⁴, Véronique Marsaud^{1,2,3} and Brigitte Sola⁴

¹CNRS, UMR 8612, Pharmacologie Cellulaire et Moléculaire des Anticancéreux, Faculté de Pharmacie, 5 rue JB Clément, Châtenay-Malabry F-92296, France

²Université Paris-Sud, Orsay F-91405, France

³IFR 141, Châtenay-Malabry F-92296, France

⁴Biologie moléculaire et cellulaire de la signalisation, EA 3919, IFR 186, Université de Caen-Basse Normandie, 14000 Caen, France

(Correspondence should be addressed to J-M Renoir; Email: michel.renoir@u-psud.fr)

Abstract

Antioestrogens (AEs) are synthetic molecules that block proliferation and induce apoptosis in breast cancer (BC) cells, principally by competing with oestradiol for binding to oestrogen receptors. Their antiproliferative activity and their pro-apoptotic capacity are well documented and a small number of molecules of this class are currently used clinically for the treatment of BC. AEs also inhibit cell cycle progression and/or induce apoptosis in multiple myeloma (MM) cells. Encouraging preliminary results have been obtained with patients and on xenografts with MM, providing a rational basis for the clinical use of AEs. This review focuses on antioestrogen-mediated signalling for blocking targets involved in the cell cycle, survival and apoptosis in both BC and MM cells. Improvement in our understanding of the mechanisms underlying the relationships between these compounds and their targets should lead to more beneficial therapeutic strategies.

Journal of Molecular Endocrinology (2008) **40**, 101–112

Introduction

The development of hormonal treatments has led to an extensive search for highly effective and well-tolerated molecules. Antioestrogens (AEs; Fig. 1) are synthetic compounds entirely fulfilling these criteria. They inhibit the activation of two different but related ligand-induced transcription factors of the nuclear receptor superfamily: the oestrogen receptors (ER α ; Green *et al.* 1988) and ER β (Kuiper *et al.* 1996, Mosselman *et al.* 1996). ER α is the master regulator of breast cancer (BC) tumour behaviour and is much more strongly expressed in BC tumours than ER β (Dahlman-Wright *et al.* 2006). It is currently thought that ER β represses growth by inhibiting ER α -mediated transcriptional activity (Hall & McDonnell 1999, Liu *et al.* 2002, Lindberg *et al.* 2003, Faulds *et al.* 2004, Strom *et al.* 2004), and the balance between the levels of ER subtypes appears as an important regulator of the mitogenic activity of 17 beta oestradiol (E₂; Matthews *et al.* 2006, Holst *et al.* 2007). AEs block the binding of E₂ to ER α and inhibit the E₂-induced effects mediated by

the two ERs. However, this model cannot account for all the effects of AEs. Indeed, it has been shown that some ER α receptors are located in the cancer cell membrane, facilitating E₂- and DNA-independent ER activation through crosstalk with the growth factor-induced activation of cell-surface tyrosine kinase receptors (Moss *et al.* 1997, Falkenstein *et al.* 2000, Hanstein *et al.* 2004). Thus, two different types of signalling may be mediated by E₂, with nuclear (genomic) and extra-nuclear (non-genomic) effects (for reviews see (O'Malley 2005, Song *et al.* 2006)).

The ER β subtype has been identified not only in the mammary gland and both male and female reproductive tissues, but also in the colon, brain, pancreas and haematopoietic cells of the myeloid and lymphoid lineages (Enmark & Gustafsson 1999, Shim *et al.* 2003). Several groups have shown that AEs block proliferation and induce apoptosis in multiple myeloma (MM) cells, as in BC cells (Treon *et al.* 1998, Otsuki *et al.* 2000, Gauduchon *et al.* 2005, Olivier *et al.* 2006). In recent years, we have focused on deciphering the molecular mechanisms by which

Figure 1 Chemical structures of antioestrogens. 4-hydroxy-tamoxifen (4-HT), the active metabolite of tamoxifen and raloxifen belong to the selective oestrogen receptor modulator (SERMs) family. The members of this family act either as E_2 -agonists or -antagonists depending on ER subtype and cell context. ICI 182 780 and RU58668 are selective oestrogen receptor down-regulators (SERDs), acting as pure antioestrogens.

AEs, both selective oestrogen receptor modulators (SERMs), such as 4-hydroxy-tamoxifen (4-HT), and selective oestrogen receptor down-regulators (SERDs), such as ICI 182 780 (ICI or Faslodex®) and RU58668 (RU), arrest the cell cycle and/or induce apoptosis in hormone-dependent BC and MM cells. We provide here a review of some of our data. Despite the use of different molecular partners, the signalling pathways involved in cell cycle arrest and the induction of apoptosis by these AEs are similar regardless of the type of cancer cell considered.

Oestrogens and antioestrogen effects in mammary gland cells

Growth and anti-apoptotic properties of oestrogens

ERs are the predominant target of E_2 in the mammary gland. We will not describe the mechanism of action of these transcription factors in detail here, because many reviews have covered the latest discoveries concerning nuclear and membrane ER activities and clinical studies (Osborne & Schiff 2005, Heldring *et al.* 2007, Jordan & Brodie 2007, Lonard & O'Malley 2007, Popov *et al.* 2007). In the mammary gland, E_2 promotes cell

proliferation in both normal and transformed epithelial cells by modifying the expression of hormone-responsive genes involved in the cell cycle and/or programmed cell death. In ER-positive human BC MCF-7 cells, the principal action of E_2 is the induction of proliferation through the stimulation of G1- to S-phase transition. This induction is associated with the rapid and direct up-regulation of c-myc, which controls cyclin D1 expression, the activation of cyclin-dependent kinase (Cdk) and the phosphorylation of retinoblastoma protein (pRb; Fig. 2; Altucci *et al.* 1996, Foster & Wimalasena 1996, Hurd *et al.* 1997, Prall *et al.* 1997, Doisneau-Sixou *et al.* 2003). Evidence for a key role of c-myc in E_2 action has been obtained from experiments showing that antisense oligonucleotides inhibit E_2 stimulated BC cell proliferation (Watson *et al.* 1991) and that the induction of c-Myc in AE-arrested cells can mimic the effects of E_2 by reinitiating cell cycle progression (Prall *et al.* 1998). The mitogenic and anti-apoptotic activities of E_2 are combined through the activation of *bcl-2* gene expression and the production of smaller amounts of p53 and caspase-3 in primary cultures of normal mammary epithelial cells (Somai *et al.* 2003). Moreover, E_2 /ER α complexes bind directly to a cAMP-response element and a more distal Sp1 site on the cyclin D1 promoter, leading to an increase in cyclin D1 mRNA levels (Altucci *et al.* 1996, Prall *et al.*

Figure 2 Schematic illustration of the activities of oestradiol and antioestrogens in MCF-7 cells. Following E₂ treatment, a rapid transcription-mediated increase (↗) in c-myc expression occurs, facilitating cyclin E-Cdk2 activation and entry into S phase. Concomitantly, E₂ down-regulates (↘) p21^{Cip1} and p27^{Kip1} and increases cyclin D1 levels. The formation of complexes containing Cdk4 and sequestering Ckis is enhanced. Ckis levels are down-regulated upon c-myc expression. All these events initiate the phosphorylation of pRb. Cyclin D1 in bold typeface: increase in cyclin D1 levels with activated cyclin-Cdk complexes; *increase in Cdk activity. In grey boxes, low levels of Cki. In black, E₂-mediated effects. In red, AE-mediated inhibition leading to cell cycle arrest in G₀/G₁. Refer to text for details and references.

1997, Sabbah *et al.* 1999, Castro-Rivera *et al.* 2001). ERβ competes with ERα in the induction of cyclin D1 transcription (Liu *et al.* 2002).

E₂ also rapidly activates cyclin E-Cdk2 complexes and, by relieving the inhibition mediated by the natural Cdk inhibitor (Cki) p21^{Cip1}, accelerates the G1 to S transition (Foster & Wimalasena 1996, Planas-Silva & Weinberg 1997, Prall *et al.* 1997, 2001). Another key element of the regulatory apparatus of the G1 phase is Cki p27^{Kip1}, which inhibits both Cdk2 activity in G0 and early G1 and acts as an assembly factor for cyclin D-Cdk4/6 complexes in early G1 (see Sherr & Roberts 1999, for a review). The functional expression of p27^{Kip1} is essential for normal proliferative responses in the mammary epithelium (Muraoka *et al.* 2001). E₂ activates cyclin E-Cdk2 complexes in MCF-7 cells, and the G1-S transition is associated with a decrease in the levels and activities of p27^{Kip1} and p21^{Cip1} (Foster & Wimalasena 1996, Prall *et al.* 1997, Foster *et al.* 2001; Fig. 2). Moreover, E₂ up-regulates Bcl-2 protein levels in MCF-7, T47-D and ZR-75-1 BC cells (Gompel *et al.* 2000).

Growth inhibition of AEs

The growth-inhibiting effects of AEs in ER-positive BC cells and normal epithelial mammalian cells result from cell cycle arrest in the G₀/G₁ phase (Musgrove *et al.* 1993, Doisneau-Sixou *et al.* 2003, Somai *et al.* 2003, Jamerson

et al. 2004). This antiproliferative activity is associated with the inhibition of Cdk activity and a decrease in pRb phosphorylation (Watts *et al.* 1995). In addition to the cell cycle regulator c-Myc (Jamerson *et al.* 2004), AEs target cyclin D1, cyclin E, p21^{Cip1} and p27^{Kip1} (Caldon *et al.* 2006). Both Cki molecules are weakly expressed in mammary cells, such as BC cells, but exposure to 4-HT, ICI or RU strongly increases their expression (Cariou *et al.* 2000, Slingerland & Pagano 2000, Foster *et al.* 2003). Inhibition of the expression of either p21^{Cip1} or p27^{Kip1} with antisense oligonucleotides maintains Cdk2 in an active state and prevents AE-mediated G1 blockade (Cariou *et al.* 2000, Carroll *et al.* 2000). AEs from different classes have different effects on ERα-positive BC cells: 4-HT blocks these cells in the G1 phase, whereas ICI and RU render these cells quiescent (Carroll *et al.* 2000, 2003; Fig. 2).

Pro-apoptotic activity of AEs

Mitochondria are known to play an integral role in apoptosis, and it was demonstrated that tamoxifen (Tam) induces increased rate of apoptosis after long-term treatment (Thiantanawat *et al.* 2003). Caspase-3 and caspase-7 are the most commonly studied effector caspases. When activated, they directly target proteins involved in cell integrity and are responsible for the final stage of cell death (Strasser *et al.* 2000). Specific caspase activation cascades are dependent on apoptotic stimuli (Riggins *et al.* 2005a). T47-D and ZR-75-1 cells contain caspase-3 that is absent from MCF-7 cells (Janicke *et al.* 1998). In MCF-7 cells, apoptosis proceeds via the sequential activation of caspase-7 and caspase-6 (Table 1). However, Tam increases the activity of caspases-3 in ER-negative BC cells (Mandlekar *et al.* 2000) and of caspase-9, caspase-6 and caspase-7 in MCF-7 cells (Thiantanawat *et al.* 2003) with concomitant down-regulation of Bcl-2 and up-regulation of Bax. In T47-D cells, Tam treatment activates caspase-3 (Ellis *et al.* 2003). It was also shown that in MCF-7 cells and rat mammary tumours, well known to resemble human BC tumours, Tam causes activation of caspase-8, a caspase normally related to membrane death receptor activation (Mandlekar *et al.* 2000). Indeed, caspase inhibitor z-VAD-fmk completely blocks Tam-induced apoptosis (Mandlekar *et al.* 2000). Although intriguing, these data suggest that AEs may affect both intrinsic (via caspase-9 activation) and extrinsic (via caspase-8 activation) apoptotic pathways.

Both SERMs like Tam and SERDs like ICI and RU induce moderate apoptosis in MCF-7 cells (Kandouz *et al.* 1999, Gompel *et al.* 2000) accompanied by poly-(ADP-ribose) polymerase (PARP) cleavage. These apoptotic properties are observed at micromolar concentrations of AEs in all BC cells, whereas cell cycle blockade occurs at nanomolar concentrations of AEs, suggesting that these two processes are independent and triggered by separated pathways. It was recently shown that

Table 1 Comparison of the apoptotic effects of selective oestrogen receptor modulators (SERMs) and selective oestrogen receptor down-regulators (SERDs) in breast cancer and multiple myeloma cells

	BC cells				MM cells			
	MCF-7		T47-D		RPMI 8226		LP-1	
	4-HT	RU	4-HT	RU	4-HT	RU	4-HT	RU
Death ligand/receptor								
TNF/TNFR	↗	↗	ND	ND	ND	ND	ND	ND
TRAIL/DR4/5	ND	ND	ND	ND	→ (a)	→	→ (a)	→
FasL/Fas	↗	↗ (a)	↗	↗ (a)	→	→ (a)	→	→ (a)
Bcl-2 family								
Bcl-2	↘	↘ (b)	↘	↘	→	→	→	→
Bcl-XL	ND	ND	ND	ND	→	→ (a)	→	→ (a)
Bax	→ (a)	→ (a)	→ (a)	→ (a)	→	→ (a)	→	→ (a)
Bik	→ (a)	↗ (b)	ND	ND	ND	ND	ND	ND
Mcl-1	→ (a)	≪ (b)	ND	≪ (b)	ND	≪	↘	↘ (a)
Caspase								
Caspase-3	ab	ab	↗	↗ (a)	↗	↗	↗	↗
Caspase-4	ND	ND	ND	ND	ND	↗	ND	→
Caspase-7	↗	↗	ND	ND	ND	ND	ND	ND
Caspase-8	↗	ND	ND	ND	↗	↗	↗	↗
Caspase-9	↗	ND	ND	ND	↗	↗	↗	↗

↗, enhanced or activated for caspase; ↘, decreased; →, identical; ≪, cleaved; ND, not determined; (a), our unpublished results; (b), obtained with ICI; ab, absent.

micromolar concentrations of ICI, 4-HT and raloxifen but also E₂ induce cell death due to the formation of reactive oxygen species (ROS), triggering classical caspase-dependent apoptosis (Mandlekar *et al.* 2000, Obrero *et al.* 2002, Kallio *et al.* 2005). Tam-induced production of ROS associated with release mitochondrial cytochrome *c* appears responsible for the early apoptotic effects of Tam. In addition, Tam-induced rapid death of MCF-7 cells is mediated by extracellular signal-regulated kinase signalling that can be abrogated by E₂ but not by ICI in an ER-independent mechanism (Zheng *et al.* 2007). E₂-induced apoptosis also occurs in BC cells resistant to long-term oestrogen deprivation (aromatase inhibitors) and to AEs (Gottardis *et al.* 1988, Lewis *et al.* 2005) and E₂ treatment may constitute a new clinical strategy following exhaustive antihormone therapy (Jordan *et al.* 2005).

The E₂-responsive cell lines MCF-7, T47-D and ZR75.1 all express the surface tumour necrosis factor (TNF), TRAIL and Fas-L receptors, the key mediators of the extrinsic apoptotic pathway the ligand-dependent activation of which generally results in rapid cell death. Unlike E₂, Tam up-regulates Fas-L expression (Nagarkatti & Davis 2003). However, in MCF-7 cells subjected to long periods of E₂ deprivation, E₂-induced apoptosis is correlated with Fas-L expression (Song & Santen 2003). TNF-mediated apoptosis in MCF-7 cells can be abolished by E₂ treatment, via an increase in production of the anti-apoptotic mediator Bcl-2 (Burow *et al.* 2001). Both ICI and Tam enhance TNF-induced cell death, by triggering TNF receptor production and expression at the cell surface (Smolnikar *et al.* 2000). Thus, significant crosstalk

occurs between the TNF- and AE-induced apoptosis pathways (Table 1).

Contradictory data have been published regarding the effects of AEs on the members of the Bcl-2 family. E₂ has been shown to up-regulate the anti-apoptotic Bcl-2 protein in oestrogen-dependent BC cells (Gompel *et al.* 2000), an effect counteracted by both Tam and pure AEs (Kandouz *et al.* 1999, Zhang *et al.* 1999, Ameller *et al.* 2003, Somai *et al.* 2003, Thiantanawat *et al.* 2003). In MCF-7 cells, E₂ has been shown to decrease levels of the pro-apoptotic Bak protein, whereas aromatase inhibitors or AEs have been shown to increase Bak levels (Leung *et al.* 1998, Thiantanawat *et al.* 2003). However, other studies have reported no effects of oestrogens or AEs on levels of Bax or Bak protein (Kandouz *et al.* 1999, Zhang *et al.* 1999, Gompel *et al.* 2000). There is therefore no clear consensus concerning the roles of these molecules in AE-mediated apoptosis. Bcl-XL is produced in small amounts, unaffected by AEs in BC cells. The pro-apoptotic protein Bik is down-regulated by E₂ and up-regulated by ICI, but not by the SERMs 4-HT and raloxifen (Frasor *et al.* 2003, Hur *et al.* 2004, Frasor *et al.* 2006).

Thus, in BC cells, the pro-apoptotic activity of AEs is triggered through multiple pathways that are whether dependent or independent on ER signalling.

p53

The tumour suppressor p53 is inactivated in 30% of all BCs. Together with p63 and p73, two other proteins from

the same family, p53 is a global regulator of cell cycle checkpoints and apoptosis. MCF-7 and ZR.75.1 cells contain wild-type p53, whereas T47-D cells produce a mutated form unable to bind DNA. As p53-regulated target genes, such as those encoding p21^{Cip1} and the pro-apoptotic Bax protein, are activated in response to various stimuli, and since ER α binds directly to p53 (Liu *et al.* 2006, Sayeed *et al.* 2007), it was suggested that p53 is involved in the response to AEs in BC cells. However, the effects of AEs on p53 remain unclear. It has been reported that the depletion of Tam and E₂ decreases p53 levels and that Faslodex can reverse the E₂-mediated increase in p53 levels in T-47D cells (Dinda *et al.* 2002). The group responsible for this study also showed that E₂ and Tam induce the transcriptional activity of the P1 promoter of p53 in MCF-7 cells, whereas Faslodex does not (Hurd *et al.* 1997). These data contrast with data from other studies reporting no change in p53 levels in response to Tam, despite the significant induction of apoptosis and pRb dephosphorylation (Fattman *et al.* 1998, Zhang *et al.* 1999). These differences may be due to the subcellular distribution of p53 within cells (Molinari *et al.* 2000, Lilling *et al.* 2002). Furthermore, the product of the *Mdm2* oncogene, which is overexpressed in various cancers, and encodes an E3 ubiquitin ligase, regulates the stability of ER α by forming a ternary complex with p53 (Duong *et al.* 2007). In turn, p53 and Mdm2 regulate the E₂-dependent down-regulation of ER α and, probably, susceptibility to AE (Duong *et al.* 2007). Indeed, since ER α inhibits p53-mediated transcriptional repression (Sayeed *et al.* 2007), it can be emphasised that AE induces apoptosis in BC cells by, at least in part, relieving the inhibitory activity of ER α on p53 activity.

Survival proteins

The deregulation and inappropriate activation of phosphoinositol-3-kinase (PI3K) signalling and its downstream targets, Akt and nuclear factor- κ B (NF- κ B) have been linked to cancers (Luo *et al.* 2003). The transcriptional activity of ER α is activated by constitutively activated Akt independently on the presence of E₂ but in a PI3K-dependent manner since the PI3K inhibitor wortmanin inhibits both phosphorylation (Ser-167) and activation of ER α (Sun *et al.* 2001). Such activity is abolished by ICI but not completely by Tam, implicating that Akt-activated ER α contributes to Tam resistance (Michalides *et al.* 2004, Riggins *et al.* 2005a,b). Moreover, the p85 subunit of PI3K binds to E₂-free ER α (Sun *et al.* 2001) and the overexpression of Akt protects against Tam-induced apoptosis (Campbell *et al.* 2001). However, the role of Akt in BC cells is still unclear: for example, in MCF-7 and MDA-MB-231 cells, E₂ induces PI3K/Akt activity via an ER-independent signalling pathway that is not affected by AEs (Tsai *et al.*

2001). However, Akt must be considered as a target of choice in BC therapy since its suppression prevents endocrine therapy resistance (Glaros *et al.* 2006).

The NF- κ B family of transcription factors controls various aspects of the immune system. Among the NF- κ B proteins, some possess a Rel homology domain (RHD), such as RelA (also named p65), cRel and RelB, whereas others such as the p105/p50 and the p100/p52 do not. They form hetero-complex proteins by associating with inhibitors (I κ B) of NF- κ B, which bind to and inhibit DNA binding of the RHDs (Hayden & Ghosh 2004). These complexes are activated through the activation of an externally activated I κ B kinase that phosphorylates I κ B, leading to its proteasome-mediated degradation and enabling NF- κ B-mediated transcription following nuclear translocation. As shown previously, NF- κ B binds ER (Ray *et al.* 1994) and ER inhibits NF- κ B pathway by interacting at various steps of the activation cascade (see Kalaitzidis & Gilmore 2005 and references herein). NF- κ B activity is repressed by E₂ and AEs (Nakshatri *et al.* 1997, Pratt *et al.* 2003). Members of the NF- κ B/Rel family form dimers that regulate the transcription of genes encoding regulators of proliferation (*c-myc* and cyclin D1) and inhibitors of apoptosis (Chen & Greene 2004). According to several observations, NF- κ B activity is important for mammary carcinogenesis. Several reports have indicated that SERMs (like Tam and raloxifen) as well as SERDs (like ICI) inhibit the NF- κ B activity in various cell types (see Biswas *et al.* 2005 for a review). Thus, most results suggest that inhibiting the NF- κ B pathway in BC could have therapeutic effects principally in Tam-resistant tumours treated with E₂ (Jordan 2004) or ICI (Riggins *et al.* 2005a,b).

Effects of oestrogens and AEs in MM

Expression of oestrogen receptors

Oestrogens influence the differentiation, proliferation and survival of haematopoietic cells of the B lineage (Smithson *et al.* 1998, Medina *et al.* 2000, Grimaldi *et al.* 2002) and increase the number of plasma cells and the capacity of these cells to synthesise immunoglobulins (Molina *et al.* 1999). It is therefore not surprising that normal plasma cells and plasma cells from tumours both produce oestrogen receptor mRNA and protein. Transcripts for both ER subtypes are present in MM cell lines (Fig. 3; Otsuki *et al.* 2000), together with protein isoforms (Treon *et al.* 1998, Gauduchon *et al.* 2005, Maillard *et al.* 2006, Olivier *et al.* 2006). However, these proteins are expressed in small amounts and are difficult to detect by immunoblotting. This is particularly true for ER β , for which the quality of commercially available antibodies is low. In contrast to previous

Figure 3 Oestradiol receptors in breast cancer and multiple myeloma cells. BC (MCF-7ras, T47D, MDA-MB231, MCF-7) and MM (LP-1, Karpas 620, RPMI 8226, U266, NCI-H929, OPM-2) cells were switched to phenol red-free media containing 10% charcoal-dextran stripped fetal calf serum 3 days before total RNA isolation with Trizol reagent (Invitrogen). Purified RNA was reverse transcribed with M-MuLV reverse transcriptase (Invitrogen), according to the manufacturer's instructions. PCR was carried out with *Platinum Taq* polymerase (Invitrogen). The primer sequences were as follows: β -actin (forward: 5'-tgacggggtcaccacactgtgcc-catcta-3', reverse: 5'-ctagaagcatttgcgtggacgatggagg-3'), ER α (forward: 5'-gtggcctcgttttagtc-3', reverse: 5'-tcacctgtgagagaa-cag-3'), ER β (forward: 5'-tcacatctgtatgcggaacc-3', reverse: 5'-cgtaacacttccgaagtcgg-3').

reports (Olivier *et al.* 2006), we found that the levels of ER α and β in MM cells never reached those in MCF-7 cells (Gauduchon *et al.* 2003, 2005). As a result, hormone-binding detection assays based on the use of tritiated high-affinity oestrogens have always been unsuccessful in our hands (unpublished data).

Effects of oestrogens and AEs on MM cell proliferation

E₂ and AEs are anti-proliferative in MM cells (Treon *et al.* 1998, Otsuki *et al.* 2000, Gauduchon *et al.* 2005, Olivier *et al.* 2006). At high concentrations (0.5 to 50 μ M), AEs arrest the cell cycle in MM cells at the G1 (Gauduchon *et al.* 2005, Table 2) or the G2 phase (Olivier *et al.* 2006) depending on the type of AE used. However, in all cases,

Table 2 Antioestrogen-mediated cell cycle arrests and induction of apoptosis in multiple myeloma cells

	4-HT	RU	ICI
U266	G1 arrest + apoptosis	No response	nd
RPMI 8226	G1 arrest + apoptosis	Apoptosis	Apoptosis
NCI-H929	G1 arrest + apoptosis	Apoptosis	Apoptosis
OPM-2	No response	G1 arrest	G1 arrest
Karpas 620	No response	No response	nd
LP-1	G1 arrest + apoptosis	G1 arrest	G1 arrest

nd, not determined.

cell cycle arrest is mediated by the down-regulation of c-myc followed by the up-regulation and redistribution of p21^{Cip1} and p27^{Kip1} within the cyclin D/E/Cdk complexes, leading to the hypophosphorylation of pRb (Gauduchon *et al.* 2005, Olivier *et al.* 2006, Table 2). A similar situation is observed in BC cells, except that the mediators of AE-mediated cell cycle arrest appear to be cell specific (Sola & Renoir 2007; Fig. 4).

Effects of AEs on the apoptosis of MM cells

In addition to their anti-proliferative activity, AEs also trigger MM cell apoptosis at micromolar concentrations (Table 2; Treon *et al.* 1998, Otsuki *et al.* 2000, Gauduchon *et al.* 2005, Olivier *et al.* 2006). The fact that U266 and Karpas 620 cell lines are listed as not responsive to RU in the face of being ER positive (Fig. 3) may be due to an insufficient (or no) ER protein expression despite the presence of the mRNAs. In agreement with that, using western blot analysis, we did not see the ER protein in Karpas 620 cells (Gauduchon *et al.* 2005). The lack of AE response could be also due to the absence of co-activators or overexpression of co-repressors as suggested previously (Shim *et al.* 2003, Shim *et al.* 2006, Sola & Renoir 2006). Moreover, the response to 4-HT may be attributable to the production of ROS at micromolar 4-HT concentration.

Cell cycle arrest and apoptosis induction are independent phenomena occurring simultaneously following the treatment with 4-HT and RU or ICI (Gauduchon *et al.* 2005). AEs activate the mitochondrial intrinsic death pathway (Treon *et al.* 1998, Otsuki *et al.* 2000, Gauduchon *et al.* 2005, Olivier *et al.* 2006) and may also activate the endoplasmic reticulum death pathway, according to plasma cell physiology. Following the AE-induced apoptotic signal, cytochrome *c* is released from the mitochondria and activates caspase-9 or caspase-4 and then caspase-3 (Fig. 5). Apoptosis signalling is amplified by the recruitment of caspase-8 and the cleavage of Bid (Maillard *et al.* 2006), but does not require the extrinsic death receptor pathways mediated by Fas/FasL and DR4/5/TRAIL (our unpublished data).

Effects of AEs on MM survival signalling

MM cells display constitutive activation of survival signalling pathways, including the Ras/mitogen-activated protein kinase (MAPK), Janus kinase (Jak)/signal transducer and activator of transcription (STAT), NF- κ B, phosphoinositol-3-kinase (PI3K)/Akt pathways (Bommert *et al.* 2006). To be effective, anti-myeloma agents must therefore target one or several of these pathways. Moreover, the ability to inhibit survival pathways seems to be essential for the treatment of MM resistant to conventional drugs (Hideshima *et al.* 2007).

Figure 4 Mechanism of cell cycle arrest in multiple myeloma cells. Cultured LP-1 MM cells were treated with 10 μ M RU (+) for 24 h or left untreated (–) and harvested. Total proteins were extracted, separated by SDS-PAGE, transferred onto membranes then incubated with various antibodies (anti-c-Myc, anti-p27^{Kip1}, anti-cyclin D3, anti-phospho-pRb antibodies). In MM cells, RU down-regulates c-Myc, its primary target, and consequently cyclin D3. In the mean time, there is an up-regulation of the cki p27^{Kip1} that binds the cyclin D3/CDK6 complexes. Finally, the inhibition of cdk activity leads to the hypophosphorylation of pRb and the cell cycle arrest at the G1 phase.

As in some BC cells, it has been shown that the NF- κ B p65 subunit is associated with ER α in the nucleus of MM cell lines although weakly. Upon raloxifen treatment, there is a transient increase in the p65/NF- κ B interaction and simultaneously a loss of p65 binding on specific gene promoters such as mip-1 α (Olivier *et al.* 2006). We do not have evidence of any interaction between ER α and NF- κ B subunits in MM cells after RU treatment. Nevertheless,

RU induces an inhibition of I κ B kinase activity in RPMI 8226 cells that undergo apoptosis (Fig. 6) and inhibits p65 binding on its DNA target (data not shown). RU also interferes with the STAT3 and Akt pathways by modulating the phosphorylation of signal transducers (Fig. 6). However, the demonstration that the inhibition of these survival pathways is necessary for apoptosis triggering needs some additional work.

Figure 5 Schematic illustration of the apoptotic pathways activated by antioestrogens in breast cancer and multiple myeloma cells. At micromolar concentrations, AEs activate the intrinsic mitochondrial pathway by inducing the release of cytochrome c and the successive activation of caspase-9 and caspase-3 in MM cells (replaced by caspase-6/7 in MCF-7 cells), leading to the cleavage of PARP. In MM cells, RU and ICI also induce apoptosis by activating caspase-4, which, in turn, activates caspase-3. Finally, the activation of caspase-8 leads to the cleavage of Bid, resulting in the amplification of caspase-9 activation, further increasing the level of apoptosis. ER, endoplasmic reticulum.

Effects of AEs in MM xenografts

Although not reproducing the exact human pathology, a commonly used model using s.c. injection of RPMI 8226 cells in nude mice was developed (Chauhan *et al.* 2002, Cuendet *et al.* 2004). This type of tumour preserves neo-angiogenic characteristics necessary for the development of the disease. Using a stealth liposomal delivery system, we have demonstrated that both RU (Maillard *et al.* 2005, 2006) and 4-HT (manuscript in preparation) induced a decrease of RPMI 8226 tumour growth. In addition, AE-targeted to solid tumours by delivery systems such as those generated for RPMI 8226 (Maillard *et al.* 2006) and MCF-7 xenografts induce strong anti-angiogenesis, potentiating the anti-proliferative and apoptotic activities of AEs (Renoir *et al.* 2006).

Conclusions

These data demonstrate that, in ER-positive BC and MM cell lines, both types of AE arrest the cell cycle and/or induce apoptosis via two independent and separate but similar pathways. Indeed, AEs initially target c-myc and the cell cycle machinery, but cyclin D3 and p27^{Kip1} in MM cells replacing the cyclin D1 and p21^{Cip1} targeted in BC cells. AEs trigger the mitochondrial intrinsic death pathway in BC cells and

Figure 6 Effects of RU on survival pathways activated in MM cells. MM cells are characterised by the constitutive activation of pathways involved in survival signalling: PI3K/Akt, Jak/Stat3, Ras/MAPK or NF-κB. This is illustrated by the constitutive phosphorylation of proteins involved in the signalisation cascade. Using phospho-specific antibodies, we analysed the effects of RU on two MM cell lines: LP-1 and RPMI 8226. RU treatment of LP-1 cells blocks cell cycle but has no effects on cell death; by contrast, RU induces RPMI 8226 cell apoptosis but had no effects on cell cycle. The Akt pathway is activated in both cell lines. In LP-1 cells, RU has no effects on pAkt (Ser473 and Thr 308) or the phosphatase PTEN. In RPMI 8226 cells, RU treatment leads to a decrease of Akt and in turn in its phosphorylated form. RPMI 8226 and LP-1 cells display a constitutive activity of p65 NF-κB subunit binding on DNA (not shown). RU treatment has no effects on pIκB, the inhibitor of NF-κB, but up-regulates this form in RPMI 8226. RU has no effects on the MAPK, ERK1/2 and JNK pathways. On the Jak/Stat3 pathway, preliminary results indicate that in RPMI 8226 cells, RU down-regulates pTyr705-Stat3. Experiments are ongoing to determine whether the inhibition of the Jak/Stat3 is necessary for apoptosis to occur.

both the mitochondrial and endoplasmic reticulum death pathways in MM cells. ER ligands act in synergy with conventional molecules used in the treatment of cancer, such as dexamethasone, and bortezomib (Jordan 2007, Jordan & Brodie 2007), and encouraging preliminary results for MM xenografts (Maillard *et al.* 2006) and MM patients (Fassas *et al.* 2001) provide a rationale for the use of AEs in the clinical treatment of MM. AE compounds may be of greater value for the treatment than the original restriction of their use to E₂-dependent BCs might suggest. The chief unresolved question concerns the involvement of ER in mediating the anti-proliferative effects of AEs. Our working hypothesis is that in both BC and MM cells, AE-mediated cell cycle arrest is ER dependent, whereas apoptosis is ER independent. ERs require various

co-regulatory proteins for their function (Hall & McDonnell 2005), and the cell-specific expression of these molecules may account for differences in the actions of different ER antagonists. In addition, the discovery of membrane ER-triggered effects and cross-talk with growth factors, NF-κB and kinase cascade signalling (Gee *et al.* 2003, Kalaitzidis & Gilmore 2005, Martin *et al.* 2005, Nicholson *et al.* 2005) has greatly complicated our view of the mechanism of action of ER ligands. However, due to the large tissue distribution of ERs (and mainly ERβ), it is likely that AEs could have some positive or negative effects on various other cancers such as uterine, ovary, lung and colon cancers due to crosstalk with the above-mentioned pathways (AP1, SP1, EGFR, NF-κB, Akt/PKB). More work is clearly required to improve our understanding of the

activities of ER ligands regulation of the balance existing between ER α and ER β .

Acknowledgements

Supported by the Ligue Nationale contre le Cancer - Comités du Cher de l'Indre et des Hauts de Seine (to J-M R), Comités de la Manche et du Calvados (to B S), the Association pour la Recherche sur le Cancer (fellowship to C B and A S). The authors declare no conflict of interest that would prejudice impartiality of the research.

References

- Altucci L, Addeo R, Cicatiello S, Dauvois S, Parker MG, Truss M, Beato M, Sica F, Bresciani F & Weisz A 1996 17 β -Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. *Oncogene* **12** 2315–2324.
- Ameller T, Marsaud V, Legrand P, Gref R & Renoir JM 2003 *In vitro* and *in vivo* biologic evaluation of long-circulating biodegradable drug carriers loaded with the pure antiestrogen RU 58668. *International Journal of Cancer* **106** 446–454.
- Biswas DK, Singh S, Shi Q, Pardee AB & Iglehart JD 2005 Crossroads of estrogen receptor and NF- κ B signaling. *Science's STKE* **2005** pe27.
- Bommert K, Bargou RC & Stuhmer T 2006 Signalling and survival pathways in multiple myeloma. *European Journal of Cancer* **42** 1574–1580.
- Burow ME, Weldon CB, Tang Y, McLachlan JA & Beckman BS 2001 Oestrogen-mediated suppression of tumour necrosis factor alpha-induced apoptosis in MCF-7 cells: subversion of Bcl-2 by anti-oestrogens. *Journal of Steroid Biochemistry and Molecular Biology* **78** 409–418.
- Caldon CE, Daly RJ, Sutherland RL & Musgrove EA 2006 Cell cycle control in breast cancer cells. *Journal of Cellular Biochemistry* **97** 261–274.
- Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S & Nakshatri H 2001 Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. *Journal of Biological Chemistry* **276** 9817–9824.
- Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N & Slingerland JM 2000 Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. *PNAS* **97** 9042–9046.
- Carroll JS, Prall OW, Musgrove EA & Sutherland RL 2000 A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. *Journal of Biological Chemistry* **275** 38221–38229.
- Carroll JS, Lynch DK, Swarbrick A, Renoir JM, Sarcevic B, Daly RJ, Musgrove EA & Sutherland RL 2003 p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells. *Cancer Research* **63** 4322–4326.
- Castro-Rivera E, Samudio I & Safe S 2001 Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. *Journal of Biological Chemistry* **276** 30853–30861.
- Chauhan D, Catley L, Hideshima T, Li G, Leblanc R, Gupta T, Slatter M, Richardson P, Schlossman R, Podar K *et al.* 2002 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. *Blood* **100** 2187–2194.
- Chen LF & Greene WC 2004 Shaping the nuclear action of NF- κ B. *Nature Reviews. Molecular Cell Biology* **5** 392–401.
- Cuendet M, Christov K, Lantvit DD, Deng Y, Hedayat S, Helson L, McChesney JD & Pezzuto JM 2004 Multiple myeloma regression mediated by bruceantin. *Clinical Cancer Research* **10** 1170–1179.
- Dahlman-Wright K, Cavaillès V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG & Gustafsson JA 2006 International Union of Pharmacology. LXIV. Estrogen receptors. *Pharmacological Reviews* **58** 773–781.
- Dinda S, Sanchez A & Moudgil V 2002 Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. *Oncogene* **21** 761–768.
- Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA & Sutherland RL 2003 Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. *Endocrine Related Cancer* **10** 179–186.
- Duong V, Boule N, Daujat S, Chauvet J, Bonnet S, Neel H & Cavaillès V 2007 Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents. *Cancer Research* **67** 5513–5521.
- Ellis CA, Vos MD, Wickline M, Riley C, Vallecorsa T, Telford WG, Zujewski J & Clark GJ 2003 Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines. *Breast Cancer Research and Treatment* **78** 59–67.
- Enmark E & Gustafsson JA 1999 Oestrogen receptors – an overview. *Journal of Internal Medicine* **246** 133–138.
- Falkenstein E, Tillmann HC, Christ M, Feuring M & Wehling M 2000 Multiple actions of steroid hormones—a focus on rapid, non-genomic effects. *Pharmacological Reviews* **52** 513–556.
- Fassas AB, Rapoport AP, Bolanos-Meade J, Shanholtz C, Cottler-Fox M & Tricot G 2001 Tamoxifen-based treatment induces clinically meaningful responses in multiple myeloma patients with relapsing disease after autotransplantation. *Leukemia and Lymphoma* **42** 1323–1328.
- Fattman CL, An B, Sussman L & Dou QP 1998 p53-independent dephosphorylation and cleavage of retinoblastoma protein during tamoxifen-induced apoptosis in human breast carcinoma cells. *Cancer Letters* **130** 103–113.
- Faulds MH, Olsen H, Helguero LA, Gustafsson JA & Haldosen LA 2004 Estrogen receptor functional activity changes during differentiation of mammary epithelial cells. *Molecular Endocrinology* **18** 412–421.
- Foster JS & Wimalasena J 1996 Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. *Molecular Endocrinology* **10** 488–498.
- Foster JS, Henley DC, Bukovsky A, Seth P & Wimalasena J 2001 Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function. *Molecular and Cellular Biology* **21** 794–810.
- Foster JS, Fernando RI, Ishida N, Nakayama KI & Wimalasena J 2003 Estrogens down-regulate p27Kip1 in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway. *Journal of Biological Chemistry* **278** 41355–41366.
- Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR & Katzenellenbogen BS 2003 Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. *Endocrinology* **144** 4562–4574.
- Frasor J, Chang EC, Komm B, Lin CY, Vega VB, Liu ET, Miller LD, Smeds J, Bergh J & Katzenellenbogen BS 2006 Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. *Cancer Research* **66** 7334–7340.
- Gauduchon J, Gouilleux F, Maillard S, Marsaud V, Renoir JM & Sola B 2003 The selective estrogen receptor modulator 4-hydroxy tamoxifen induces G1 arrest and apoptosis of multiple myeloma cell lines. *Annals of the New York Academy of Sciences* **1010** 321–325.
- Gauduchon J, Gouilleux F, Maillard S, Marsaud V, Renoir JM & Sola B 2005 The 4-hydroxytamoxifen inhibits proliferation of multiple

- myeloma cells *in vitro* and *in vivo* through down-regulation of c-Myc, up-regulation of p27Kip1 and modulation of Bcl-2 family members. *Clinical Cancer Research* **11** 2345–2354.
- Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jordan N, Wakeling AE & Nicholson RI 2003 The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer *in vitro*. *Endocrinology* **144** 5105–5117.
- Glaros S, Atanaskova N, Zhao C, Skafar DF & Reddy KB 2006 Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen. *Molecular Endocrinology* **20** 996–1008.
- Gompel A, Somai S, Chaouat M, Kazen A, Kloosterboer HJ, Beusman I, Forgez P, Mimoun M & Rostene W 2000 Hormonal regulation of apoptosis in breast cells and tissues. *Steroids* **65** 593–598.
- Gottardis MM, Robinson SP, Satyaswaroop PG & Jordan VC 1988 Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. *Cancer Research* **48** 812–815.
- Green S, Kumar V, Theulaz I, Wahli W & Chambon P 1988 The N-terminal DNA-binding 'zinc finger' of the oestrogen and glucocorticoid receptors determines target gene specificity. *EMBO Journal* **7** 3037–3044.
- Grimaldi CM, Cleary J, Dagtas AS, Moussai D & Diamond B 2002 Estrogen alters thresholds for B cell apoptosis and activation. *Journal of Clinical Investigation* **109** 1625–1633.
- Hall JM & McDonnell DP 1999 The estrogen receptor beta-isoform (ER β) of the human estrogen receptor modulates ER α transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. *Endocrinology* **140** 5566–5578.
- Hall JM & McDonnell DP 2005 Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. *Molecular Interventions* **5** 343–357.
- Hanstein B, Djahansouzi S, Dall P, Beckman MW & Bender HG 2004 Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer. *European Journal of Endocrinology* **150** 243–255.
- Hayden MS & Ghosh S 2004 Signaling to NF- κ B. *Genes and Development* **18** 2195–2224.
- Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Strom A, Treuter E, Warner M *et al.* 2007 Estrogen receptors: how do they signal and what are their targets. *Physiological Reviews* **87** 905–931.
- Hideshima T, Mitsiades C, Tonon G, Richardson PG & Anderson KC 2007 Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. *Nature Reviews. Cancer* **7** 585–598.
- Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A, Terracciano L, Al-Kuray K, Janicke F *et al.* 2007 Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. *Nature Genetics* **39** 655–660.
- Hur J, Chesnes J, Coser KR, Lee RS, Geck P, Isselbacher KJ & Shioda T 2004 The Bik BH3-only protein is induced in estrogen-starved and antiestrogen-exposed breast cancer cells and provokes apoptosis. *PNAS* **101** 2351–2356.
- Hurd C, Khattree N, Dinda S, Alban P & Moudgil VK 1997 Regulation of tumor suppressor proteins, p53 and retinoblastoma, by estrogen and antiestrogens in breast cancer cells. *Oncogene* **15** 991–995.
- Jamerson MH, Johnson MD & Dickson RB 2004 Of mice and Myc: c-Myc and mammary tumorigenesis. *Journal of Mammary Gland Biology and Neoplasia* **9** 27–37.
- Janicke RU, Sprengart ML, Wati MR & Porter AG 1998 Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. *Journal of Biological Chemistry* **273** 9357–9360.
- Jordan VC 2004 Selective estrogen receptor modulation: concept and consequences in cancer. *Cancer Cell* **5** 207–213.
- Jordan VC 2007 SERMs: meeting the promise of multifunctional medicines. *Journal of the National Cancer Institute* **99** 350–356.
- Jordan VC & Brodie AM 2007 Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. *Steroids* **72** 7–25.
- Jordan VC, Lewis JS, Osipo C & Cheng D 2005 The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy. *Breast* **14** 624–630.
- Kalaitzidis D & Gilmore TD 2005 Transcription factor cross-talk: the estrogen receptor and NF- κ B. *Trends in Endocrinology and Metabolism* **16** 46–52.
- Kallio A, Zheng A, Dahllund J, Heiskanen KM & Harkonen P 2005 Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells. *Apoptosis* **10** 1395–1410.
- Kandouz M, Lombet A, Perrot JY, Jacob D, Carvajal S, Kazem A, Rostene W, Therwath A & Gompel A 1999 Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells. *Journal of Steroid Biochemistry and Molecular Biology* **69** 463–471.
- Kuiper GG, Enmark E, Peltö-Huikko M, Nilsson S & Gustafsson JA 1996 Cloning of a novel receptor expressed in rat prostate and ovary. *PNAS* **93** 5925–5930.
- Leung LK, Do L & Wang TT 1998 Regulation of death promoter Bak expression by cell density and 17 beta-estradiol in MCF-7 cells. *Cancer Letters* **124** 47–52.
- Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, Bell E, Chandel NS & Jordan VC 2005 Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. *Journal of the National Cancer Institute* **97** 1746–1759.
- Lilling G, Nordenberg J, Rotter V, Goldfinger N, Peller S & Sidi Y 2002 Altered subcellular localization of p53 in estrogen-dependent and estrogen-independent breast cancer cells. *Cancer Investigation* **20** 509–517.
- Lindberg MK, Moverare S, Skrtic S, Gao H, Dahlmann-Wright K, Gustafsson JA & Ohlsson C 2003 Estrogen receptor (ER)- β reduces ER α -regulated gene transcription, supporting a 'ying yang' relationship between ER α and ER β in mice. *Molecular Endocrinology* **17** 203–208.
- Liu MM, Albanese C, Anderson CM, Hilty K, Webb P, Uht RM, Price RH Jr, Pestell RG & Kushner PJ 2002 Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. *Journal of Biological Chemistry* **277** 24353–24360.
- Liu W, Konduri SD, Bansal S, Nayak BK, Rajasekaran SA, Karuppaiyl SM, Rajasekaran AK & Das GM 2006 Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. *Journal of Biological Chemistry* **281** 9837–9840.
- Lonard DM & O'Malley BW 2007 Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. *Molecular Cell* **27** 691–700.
- Luo J, Manning BD & Cantley LC 2003 Targeting the PI3K-Akt pathway in human cancer: rationale and promise. *Cancer Cell* **4** 257–262.
- Maillard S, Ameller T, Gauduchon J, Gougelet A, Gouilleux F, Legrand P, Marsaud V, Fattal E, Sola B & Renoir JM 2005 Innovative drug delivery nanosystems improve the anti-tumor activity *in vitro* and *in vivo* of antiestrogens in human breast cancer and multiple myeloma. *Journal of Steroid Biochemistry and Molecular Biology* **94** 111–121.
- Maillard S, Gauduchon J, Marsaud V, Gouilleux F, Connault E, Opolon P, Fattal E, Sola B & Renoir JM 2006 Improved antitumoral properties of pure antiestrogen RU 58668-loaded liposomes in multiple myeloma. *Journal of Steroid Biochemistry and Molecular Biology* **100** 67–78.
- Mandlekar S, Yu R, Tan TH & Kong AN 2000 Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. *Cancer Research* **60** 5995–6000.
- Martin LA, Farmer I, Johnston SR, Ali S & Dowset M 2005 Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. *Endocrine-Related Cancer* **12** S75–S84.

- Matthews J, Wihlen B, Tujague M, Wan J, Sttrom A & Gustafsson JA 2006 Estrogen receptor (ER) β modulates ER α -mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. *Molecular Endocrinology* **20** 534–543.
- Medina KL, Strasser A & Kincade PW 2000 Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors. *Blood* **95** 2059–2067.
- Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K, Floore A, Velds A, van't Veer L & Neefjes J 2004 Tamoxifen resistance by a conformational arrest of the estrogen receptor α after PKA activation in breast cancer. *Cancer Cell* **5** 597–605.
- Molina J, Masso F, Paez A, Mendez C, Rodriguez E, Mandoki JJ, Diaz de Leon L & Montano LF 1999 Differential effect of estradiol on antibody secretion of murine hybridomas. *Hybridoma* **18** 377–383.
- Molinari AM, Bontempo P, Schiavone EM, Tortora V, Verdiccio MA, Napolitano M, Nola E, Montchamont B, Medici N, Nigro V *et al.* 2000 Estradiol induces functional inactivation of p53 by intracellular redistribution. *Cancer Research* **60** 2594–2597.
- Moss RL, Gu Q & Wong M 1997 Estrogen: nontranscriptional signaling pathway. (discussion 68–9) *Recent Progress in Hormone Research* **52** 33–68.
- Mosselman S, Polman J & Dijkema R 1996 ER β : identification and characterization of a novel human estrogen receptor. *FEBS Letters* **392** 49–53.
- Muraoka RS, Lenferink AE, Simpson J, Brantley DM, Roebuck LR, Yakes FM & Arteaga CL 2001 Cyclin-dependent kinase inhibitor p27(Kip1) is required for mouse mammary gland morphogenesis and function. *Journal of Cell Biology* **153** 917–932.
- Musgrove EA, Hamilton JA, Lee CS, Sweeney KJ, Watts CK & Sutherland RL 1993 Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. *Molecular and Cellular Biology* **13** 3577–3587.
- Nagarkatti N & Davis BA 2003 Tamoxifen induces apoptosis in Fas+ tumor cells by upregulating the expression of Fas ligand. *Cancer Chemotherapy and Pharmacology* **51** 284–290.
- Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr & Sledge GW Jr 1997 Constitutive activation of NF- κ B during progression of breast cancer to hormone-independent growth. *Molecular and Cellular Biology* **17** 3629–3639.
- Nicholson RI, Hutchesson IR, Britton D, Knowlden JM, Jones HE, Harper ME, Hiscox SE, Barrow D & Gee JM 2005 Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. *Journal of Steroid Biochemistry and Molecular Biology* **93** 257–262.
- Obrero M, Yu DV & Shapiro DJ 2002 Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. *Journal of Biological Chemistry* **277** 45695–45703.
- Olivier S, Close P, Castermans E, de Leval L, Tabruyn S, Chariot A, Malaise M, Merville MP, Bours V & Franchimont N 2006 Raloxifene-induced myeloma cell apoptosis: a study of nuclear factor- κ B inhibition and gene expression signature. *Molecular Pharmacology* **69** 1615–1623.
- O'Malley BW 2005 A life-long search for the molecular pathways of steroid hormone action. *Molecular Endocrinology* **19** 1402–1411.
- Osborne CK & Schiff R 2005 Estrogen-receptor biology: continuing progress and therapeutic implications. *Journal of Clinical Oncology* **23** 1616–1622.
- Otsuki T, Yamada O, Kurebayashi J, Moriya T, Sakaguchi H, Kunisie H, Yata K, Uno M, Yawata Y & Ueki A 2000 Estrogen receptors in human myeloma cells. *Cancer Research* **60** 1434–1441.
- Planas-Silva MD & Weinberg RA 1997 Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. *Molecular and Cellular Biology* **17** 4059–4069.
- Popov VM, Wang C, Shirley LA, Rosenberg A, Li S, Nevalainen M, Fu M & Pestell RG 2007 The functional significance of nuclear receptor acetylation. *Steroids* **72** 221–230.
- Prall OW, Sarcevic B, Musgrove E, Watts CK & Sutherland RL 1997 Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. *Journal of Biological Chemistry* **272** 10882–10894.
- Prall OW, Rogan EM, Musgrove EA, Watts CK & Sutherland RL 1998 c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. *Molecular and Cellular Biology* **18** 4499–4508.
- Prall OW, Carroll JS & Sutherland RL 2001 A low abundance pool of nascent p21WAF1/Cip1 is targeted by estrogen to activate cyclin E-Cdk2. *Journal of Biological Chemistry* **276** 45433–45442.
- Pratt MA, Bishop TE, White D, Yasvinski G, Menard M, Niu NY & Clarke R 2003 Estrogen withdrawal-induced NF- κ B activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence. *Molecular and Cellular Biology* **23** 6887–6900.
- Ray A, Prefontaine KE & Ray P 1994 Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor. *Journal of Biological Chemistry* **269** 12940–12946.
- Renoir JM, Stella B, Ameller T, Connault E, Opolon P & Marsaud V 2006 Improved anti-tumoral capacity of mixed and pure anti-oestrogens in breast cancer cell xenografts after their administration by entrapment in colloidal nanosystems. *Journal of Steroid Biochemistry and Molecular Biology* **102** 114–127.
- Riggins RB, Bouton AH, Liu MC & Clarke R 2005a Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. *Vitamins and Hormones* **71** 201–237.
- Riggins RB, Zwart A, Nehra R & Clarke R 2005b The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. *Molecular Cancer Therapeutics* **4** 33–41.
- Sabbah M, Courilleau D, Mester J & Redeuilh G 1999 Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. *PNAS* **96** 11217–11222.
- Sayed A, Konduri SD, Liu W, Bansal S, Li F & Das GM 2007 Estrogen receptor α inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. *Cancer Research* **67** 7746–7755.
- Sherr CJ & Roberts JM 1999 CDK inhibitors: positive and negative regulators of G1-phase progression. *Genes and Development* **13** 1501–1512.
- Shim GJ, Wang L, Andersson S, Nagy N, Kis LL, Zhang Q, Makela S, Warner M & Gustafsson JA 2003 Disruption of the estrogen receptor beta gene in mice causes myeloproliferative disease resembling chronic myeloid leukemia with lymphoid blast crisis. *PNAS* **100** 6694–6699.
- Shim GJ, Gherman D, Kim HJ, Omoto Y, Iwase H, Bouton D, Kis LL, Andersson CT, Warner M & Gustafsson JA 2006 Differential expression of oestrogen receptors in human secondary lymphoid tissues. *Journal of Pathology* **208** 408–414.
- Slingerland J & Pagano M 2000 Regulation of the cdk inhibitor p27 and its deregulation in cancer. *Journal of Cellular Physiology* **183** 10–17.
- Smithson G, Couse JF, Lubahn DB, Korach KS & Kincade PW 1998 The role of estrogen receptors and androgen receptors in sex steroid regulation of B lymphopoiesis. *Journal of Immunology* **161** 27–34.
- Smolnikar K, Loffek S, Schulz T, Michna H & Diel P 2000 Treatment with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells. *Breast Cancer Research and Treatment* **63** 249–259.
- Sola B & Renoir JM 2006 Antiestrogenic therapies in solid cancers and multiple myeloma. *Current Molecular Medicine* **6** 359–368.
- Sola B & Renoir JM 2007 Estrogenic or antiestrogenic therapies for multiple myeloma? *Molecular Cancer* **6** 59.

- Somai S, Chaouat M, Jacob D, Perrot JY, Rostene W, Forgez P & Gompel A 2003 Antiestrogens are pro-apoptotic in normal human breast epithelial cells. *International Journal of Cancer* **105** 607–612.
- Song RX & Santen RJ 2003 Apoptotic action of estrogen. *Apoptosis* **8** 55–60.
- Song RX, Fan P, Yue W, Chen Y & Santen RJ 2006 Role of receptor complexes in the extranuclear actions of estrogen receptor alpha in breast cancer. *Endocrine-Related Cancer* **13** (Suppl 1) S3–S13.
- Strasser A, O'Connor L & Dixit VM 2000 Apoptosis signaling. *Annual Review of Biochemistry* **69** 217–245.
- Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J & Gustafsson JA 2004 Estrogen receptor beta inhibits 17 β -estradiol-stimulated proliferation of the breast cancer cell line T47D. *PNAS* **101** 1566–1571.
- Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV & Cheng JQ 2001 Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ER α) via interaction between ER α and PI3K. *Cancer Research* **61** 5985–5991.
- Thiantanawat A, Long BJ & Brodie AM 2003 Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. *Cancer Research* **63** 8037–8050.
- Treon SP, Teoh G, Urashima M, Ogata A, Chauhan D, Webb IJ & Anderson KC 1998 Anti-estrogens induce apoptosis of multiple myeloma cells. *Blood* **92** 1749–1757.
- Tsai EM, Wang SC, Lee JN & Hung MC 2001 Akt activation by estrogen in estrogen receptor-negative breast cancer cells. *Cancer Research* **61** 8390–8392.
- Watson PH, Pon RT & Shiu RP 1991 Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. *Cancer Research* **51** 3996–4000.
- Watts CK, Brady A, Sarcevic B, DeFazio A, Musgrove EA & Sutherland RL 1995 Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. *Molecular Endocrinology* **9** 1804–1813.
- Zhang GJ, Kimijima I, Onda M, Kanno M, Sato H, Watanabe T, Tsuchiya A, Abe R & Takenoshita S 1999 Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels. *Clinical Cancer Research* **5** 2971–2977.
- Zheng A, Kallio A & Harkonen P 2007 Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen. *Endocrinology* **148** 2764–2777.

Received in final form 18 December 2007

Accepted 14 January 2008

Made available online as an Accepted Preprint

14 January 2008